Sun Pharma will present 14 abstracts at the 2026 AAD Annual Meeting (March 27–31, Denver, Colorado) covering dermatology and immunology.
Key data covers ILUMYA (psoriasis), LEQSELVI (alopecia areata), and WINLEVI (acne), reinforcing Sun Pharma's specialty dermatology portfolio.
Sun Pharma's specialty portfolio spans dermatology, ophthalmology, and oncodermatology and accounts for over 18% of company sales.